Phreesia Inc. (PHR) Acquires Insignia Health
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Phreesia Inc. (PHR) PT Lowered to $54 at Citi
December 10, 2021 6:37 AM ESTCiti analyst Daniel Grosslight lowered the price target on Phreesia Inc. (NYSE: PHR) to $54.00 (from $72.00) while maintaining a Neutral rating.... More
Pre-Open Stock Movers 12/09: (IINN) (AVCT) (RH) Higher; (RETA) (RLMD) (GME) Lower (more...)
December 9, 2021 9:29 AM ESTPre-Open Movers:
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) 113% HIGHER; signed an exclusive summary distribution agreement with Innovimed Sp. z o.o ("Innovimed"), a master distributor specializing in state-of-the-art medical solutions in Eastern Europe, Middle East and Africa. The Innovimed leadership team, have decades of experience with sales, marketing and distribution with medical devices in global healthcare industry companies including Baxter (AG).
Reata Pharmaceuticals, Inc. (Nasdaq:... More
Phreesia Inc. (PHR) PT Lowered to $65 at Needham & Company, But 'Buyers on Weakness'
December 9, 2021 7:07 AM ESTNeedham & Company analyst Ryan MacDonald lowered the price target on Phreesia Inc. (NYSE: PHR) to $65.00 (from $81.00) while maintaining a Buy rating.
The analyst commented, "We reiterate our Buy rating, while lowering our PT to $65, following the company's 3QF22 results in which revenue... More
Phreesia Inc. (PHR) PT Lowered to $51 at RBC Capital
December 9, 2021 7:01 AM ESTRBC Capital analyst Sean Dodge lowered the price target on Phreesia Inc. (NYSE: PHR) to $51.00 (from $60.00) while maintaining a Sector Perform rating.... More
